See more : 3 Sixty Risk Solutions Ltd. (SAYFF) Income Statement Analysis – Financial Results
Complete financial analysis of Noxopharm Limited (NOX.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Noxopharm Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Cash Converters International Limited (CCV.AX) Income Statement Analysis – Financial Results
- CB Financial Services, Inc. (CBFV) Income Statement Analysis – Financial Results
- Arqit Quantum Inc. (ARQQW) Income Statement Analysis – Financial Results
- Green Block Mining Corp. (GBMC.CN) Income Statement Analysis – Financial Results
- Kuwer Industries Limited (KUWERIN.BO) Income Statement Analysis – Financial Results
Noxopharm Limited (NOX.AX)
About Noxopharm Limited
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.40M | 6.01M | 5.43M | 5.61M | 8.28M | 3.75M | 916.53K | 126.30K | 0.00 |
| Cost of Revenue | 2.94M | 154.53K | 261.51K | 261.72K | 241.45K | 62.10K | 58.89K | 30.26K | 3.35K |
| Gross Profit | -534.81K | 5.86M | 5.17M | 5.35M | 8.04M | 3.69M | 857.65K | 96.04K | -3.35K |
| Gross Profit Ratio | -22.28% | 97.43% | 95.18% | 95.33% | 97.08% | 98.34% | 93.58% | 76.04% | 0.00% |
| Research & Development | 2.94M | 10.65M | 7.78M | 6.97M | 7.33M | 6.62M | 4.11M | 816.10K | 143.13K |
| General & Administrative | 1.04M | 1.48M | 1.66M | 1.59M | 3.05M | 8.09M | 4.94M | 1.80M | 298.19K |
| Selling & Marketing | 57.94K | 192.12K | 104.49K | 128.86K | 123.95K | 351.03K | 234.32K | 161.14K | 258.40K |
| SG&A | 4.07M | 5.79M | 7.17M | 7.38M | 8.79M | 8.99M | 6.33M | 1.96M | 556.59K |
| Other Expenses | 0.00 | 1.56M | -3.43M | 13.95M | 19.92M | 3.57M | -7.64M | 126.30K | 0.00 |
| Operating Expenses | 7.00M | 16.44M | 14.95M | 14.35M | 16.12M | 15.60M | 10.44M | 3.24M | 699.72K |
| Cost & Expenses | 9.94M | 16.60M | 15.21M | 14.61M | 16.37M | 15.67M | 10.50M | 3.24M | 703.07K |
| Interest Income | 6.93K | 82.51K | 46.94K | 139.47K | 11.31K | 186.69K | 62.81K | 67.50K | 355.00 |
| Interest Expense | 31.16K | 41.00K | 77.34K | 2.20M | 3.47M | 667.20K | 238.30K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.74K | 154.53K | 261.51K | 261.72K | 241.45K | 62.10K | 58.89K | 30.26K | 3.35K |
| EBITDA | -5.95M | -20.85M | -23.70M | -5.85M | -4.53M | -15.59M | -18.93M | -3.14M | -699.72K |
| EBITDA Ratio | -247.70% | -273.55% | -275.32% | -255.83% | -194.69% | -416.03% | -1,139.26% | -2,541.15% | 0.00% |
| Operating Income | -7.54M | -16.60M | -15.21M | -14.61M | -16.37M | -15.67M | -10.50M | -3.24M | -703.07K |
| Operating Income Ratio | -313.92% | -276.12% | -280.14% | -260.50% | -197.61% | -417.69% | -1,145.69% | -2,565.11% | 0.00% |
| Total Other Income/Expenses | 1.56M | 95.50K | -1.37M | 6.30M | 7.28M | -719.23K | -8.80M | 25.85K | -1.66K |
| Income Before Tax | -5.98M | -21.04M | -24.03M | -8.31M | -8.24M | -16.32M | -19.23M | -3.05M | -704.73K |
| Income Before Tax Ratio | -249.07% | -350.10% | -442.73% | -148.10% | -99.44% | -435.21% | -2,098.23% | -2,411.66% | 0.00% |
| Income Tax Expense | -2.40M | -5.99M | -5.37M | 1.04M | -8.33M | -3.75M | -910.52K | -193.80K | 4.00 |
| Net Income | -3.58M | -15.06M | -18.67M | -9.35M | -272.09K | -11.22M | -18.28M | -3.05M | -704.73K |
| Net Income Ratio | -149.07% | -250.52% | -343.86% | -166.66% | -3.29% | -299.22% | -1,994.85% | -2,411.66% | 0.00% |
| EPS | -0.01 | -0.05 | -0.06 | -0.04 | 0.00 | -0.08 | -0.15 | -0.03 | -0.02 |
| EPS Diluted | -0.01 | -0.05 | -0.06 | -0.04 | 0.00 | -0.08 | -0.15 | -0.03 | -0.02 |
| Weighted Avg Shares Out | 292.26M | 292.24M | 291.22M | 263.85M | 138.36M | 138.15M | 119.03M | 87.57M | 33.56M |
| Weighted Avg Shares Out (Dil) | 292.24M | 292.24M | 291.22M | 263.85M | 138.36M | 138.15M | 119.03M | 87.57M | 33.56M |
Source: https://incomestatements.info
Category: Stock Reports